Metformax 500 (Metformin Hydrochloride)

Metformin lowers blood sugar primarily by inhibiting hepatic gluconeogenesis, which reduces the amount of glucose released by the liver. It also activates AMP‑activated protein kinase (AMPK), enhancing insulin‑mediated glucose uptake in muscle and fat tissues, thereby improving overall insulin sensitivity.

The appropriate dose of Metformax 500 is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Metformax 500 is classified as a pregnancy‑category drug with limited data. It should only be used during pregnancy or lactation if the potential benefits outweigh the risks, and this decision must be made by a qualified prescriber after a thorough assessment.

To order Metformax 500, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformax 500 belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, and SGLT2 inhibitors. It does not stimulate insulin secretion, reducing the risk of hypoglycemia, and is often used as first‑line therapy because of its efficacy, weight‑neutral profile and low cost compared with newer agents.

Metformax 500 tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Metformax 500 is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, heart failure, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformax 500 is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and those who have experienced lactic acidosis while on metformin. It should also be used with caution in patients with liver disease or heart failure.